
    
      This was a randomized, open-label, active-control, multicenter study to evaluate efficacy,
      safety, and pharmacokinetics of ABT-493/ABT-530 in chronic HCV GT2-infected direct-acting
      antiviral agent (DAA) treatment-na√Øve Japanese adult participants without cirrhosis. The
      participants were randomized in a 2:1 ratio to ABT-493/ABT-530 for 8 weeks (Arm A) and
      sofosbuvir plus ribavirin for 12 weeks (Arm B).
    
  